Fosun Diagnostics obtained CE mark for Its Self-developed Covid-19 Antigen CARD Kit
Release Time：2022-05-11 Author： Source: Pageviews：
On 10 May 2022, the Covid-19 Antigen CARD Kit (the Kit) self-developed by Fosun Diagnostics, a subsidiary company of Fosun Pharma was awarded the CE certificate and it will be now made available across 27 EU countries as well as regions that recognize the CE marked.
This Kit has significant advantages such as being accurate, fast and convenient which can be easily performed by individuals with results obtained only in 15 minutes. Applicable to the rapid testing in hospitals, CDCs, customs, airports, communities, schools, companies and other COVID-19 hot spot management as part of our efforts in continuous contribution toward the prevention and control of COVID-19 pandemic worldwide.
Prior to the CE marked, the Kit had also obtained BfArM registration in Germany, and endorsed by the EU Health Security Committee Common List (EU common list).
Fosun Diagnostics has developed an overall solution for 2019-nCoV testing, the COVID-19 RT-PCR Detection Kit is another classic product of Fosun Diagnostics with NMPA registration certificate, CE mark and FDA Emergency Use Authorization (EUA) and WHO Emergency Use Listing (EUL). The Company’s comprehensive range covers reagents, instruments, consumables, etc. have been successfully exported to numerous countries worldwide.
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
Guided by the 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values as well as promoting the global networks through strengthening its innovative R&D and in-licensing ability and enriching its product pipelines. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global mainstream medical and health market.
For more information, please visit our official website: www.fosunpharma.com.